During the past decade, FirstHealth Outpatient Cancer Center conducted 19 clinical trials. In the 10-year time frame, 19 clinical trials started and 4 clinical trials were completed, i.e. on average, 21.1% percent of trials that started reached the finish line to date. In the past 5 years, 10 clinical trials started and 3 clinical trials were completed. i.e. 30% of trials that started reached the finish line.

Out of the total clinical trials conducted in "FirstHealth Outpatient Cancer Center" #1 sponsor was "Amgen" with 2 trials, followed by "BioAtla, Inc." with 2 trials sponsored, "Exact Sciences Corporation" with 2 trials sponsored, "Gilead Sciences" with 2 trials sponsored and "PharmaMar" with 2 trials sponsored. Other sponsors include 4 different institutions and companies that sponsored additional 14 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "FirstHealth Outpatient Cancer Center" #1 collaborator was "Bayer" with 1 trials as a collaborator, "Breast Cancer Trials, Australia and New Zealand" with 1 trials as a collaborator, "Fondazione Michelangelo" with 1 trials as a collaborator, "GOG Foundation" with 1 trials as a collaborator and "German Breast Group" with 1 trials as a collaborator. Other collaborators include 4 different institutions and companies that were collaborators in the rest 14 trials.

According to Clinical.Site data, the most researched conditions in "FirstHealth Outpatient Cancer Center" are "Gastric Cancer" (3 trials), "Cervical Cancer" (2 trials), "Gastroesophageal Junction Adenocarcinoma" (2 trials), "Advanced Cancer" (1 trials) and "Carcinoma, Pancreatic Ductal" (1 trials). Many other conditions were trialed in "FirstHealth Outpatient Cancer Center" in a lesser frequency.

Most popular intervention types in "FirstHealth Outpatient Cancer Center" are "Drug" (14 trials), "Biological" (4 trials), "Other" (3 trials) and "Device" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (4 trials), "Bemarituzumab" (3 trials), "PD-1 inhibitor" (2 trials), "Pembrolizumab" (2 trials) and "Sacituzumab Govitecan-hziy (SG)" (2 trials). Other intervention names were less common.

The vast majority of trials in "FirstHealth Outpatient Cancer Center" are 16 trials for "All" genders and 3 trials for "Female" genders.

Currently, there are NaN active trials in "FirstHealth Outpatient Cancer Center". undefined are not yet recruiting, 10 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in FirstHealth Outpatient Cancer Center, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in FirstHealth Outpatient Cancer Center, 2 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 10 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".